Table 3.

Associations of Heme Oxygenase-1 Genotype With the Primary and Extended Cardiovascular End Points

Repeat Length GroupAdjustment
NoneAge and SexMultivariable*
HR (95% CI)P ValueHR (95% CI)P ValueHR (95% CI)P Value
Primary cardiovascular end point
 SS/SM0.49 (0.16, 1.55)0.2260.62 (0.20, 1.97)0.4200.68 (0.21, 2.15)0.507
 MM1.00 (ref)1.00 (ref)1.00 (ref)
 ML0.99 (0.59, 1.67)0.9711.15 (0.68, 1.95)0.5991.11 (0.65, 1.88)0.705
 LL4.78 (2.10, 10.88)<0.0015.46 (2.39, 12.50)<0.00016.33 (2.74, 14.64)<0.0001
 LL vs other4.90 (2.16, 11.13)<0.0015.45 (2.39, 12.42)<0.00016.33 (2.75, 14.59)<0.0001
Extended cardiovascular end point
 SS/SM0.39 (0.12, 1.23)0.1090.47 (0.15, 1.49)0.2020.50 (0.16, 1.57)0.235
 MM1.00 (ref)1.00 (ref)1.00 (ref)
 ML1.02 (0.64, 1.64)0.9251.20 (0.75, 1.92)0.4551.16 (0.72, 1.87)0.532
 LL5.07 (2.36, 10.88)<0.00015.88 (2.72, 12.68)<0.00016.55 (3.01, 14.30)<0.0001
 LL vs other5.21 (2.43, 11.14)<0.00015.87 (2.73, 12.63)<0.00016.56 (3.02, 14.26)<0.0001
  • The primary cardiovascular end point included nonfatal stroke, nonfatal myocardial infarction, and vascular death. The extended cardiovascular end point additionally included peripheral vascular disease and revascularization procedures.

  • * Multivariable adjustment was for age, sex, total and high-density lipoprotein cholesterol, current smoking, diabetes mellitus, systolic blood pressure, and body mass index.

  • CI indicates confidence interval; and HR, hazard ratio.